| 51 |
25561870 | Modulation of CYP2D6 and CYP3A4 metabolic activities by Ferula asafetida resin. | 2014 Dec |
1 |
| 52 |
22886152 | ABCB1 polymorphisms are associated with cyclosporine-induced nephrotoxicity and gingival hyperplasia in renal transplant recipients. | 2013 Mar |
1 |
| 53 |
23252948 | CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy. | 2013 Jan |
4 |
| 54 |
23557867 | CYP3A4/5 polymorphisms affect the blood level of cyclosporine and tacrolimus in Chinese renal transplant recipients. | 2013 Jun |
3 |
| 55 |
23841924 | [Low cyclosporin levels induced by the brief use of rifampicin; immunosuppression may fail for several weeks]. | 2013 |
1 |
| 56 |
22205779 | Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro. | 2012 Apr |
5 |
| 57 |
22388796 | The new CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-treated kidney transplant patients. | 2012 May |
2 |
| 58 |
22476221 | Hepatitis C virus treatment and liver transplantation in the era of new antiviral therapies. | 2012 Jun |
1 |
| 59 |
22576324 | Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. | 2012 Nov |
1 |
| 60 |
23018254 | Impact of CYP3A4*1B and CYP3A5*3 polymorphisms on the pharmacokinetics of cyclosporine and sirolimus in renal transplant recipients. | 2012 Jul-Sep |
6 |
| 61 |
23085740 | Association of CYP3A polymorphisms with the pharmacokinetics of cyclosporine A in early post-renal transplant recipients in China. | 2012 Dec |
3 |
| 62 |
23217392 | CYP3A4 genetic polymorphisms predict cyclosporine-related clinical events in Chinese renal transplant recipients. | 2012 Dec |
6 |
| 63 |
21349923 | Seasonal variation in blood drug concentrations and a potential relationship to vitamin D. | 2011 May |
1 |
| 64 |
21466223 | Quercetin and rutin reduced the bioavailability of cyclosporine from Neoral, an immunosuppressant, through activating P-glycoprotein and CYP 3A4. | 2011 May 11 |
5 |
| 65 |
21480191 | Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors. | 2011 Aug |
1 |
| 66 |
21753749 | In vivo CYP3A activity is significantly lower in cyclosporine-treated as compared with tacrolimus-treated renal allograft recipients. | 2011 Sep |
6 |
| 67 |
21857093 | Influence of ABCB1, CYP3A4*18B and CYP3A5*3 polymorphisms on cyclosporine A pharmacokinetics in bone marrow transplant recipients. | 2011 |
2 |
| 68 |
21902502 | Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients. | 2011 Oct |
3 |
| 69 |
22016125 | [Drug interactions and immunosuppression in organ transplant recipients]. | 2011 Oct 18 |
1 |
| 70 |
19823813 | Is cyclosporine A transport inhibited by pravastatin via multidrug resistant protein 2? | 2010 Feb |
1 |
| 71 |
20170205 | Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I. | 2010 Mar |
1 |
| 72 |
20416375 | The PXR is a drug target for chronic inflammatory liver disease. | 2010 May 31 |
1 |
| 73 |
20599501 | Investigation of Orlistat effects on PXR activation and CYP3A4 expression in primary human hepatocytes and human intestinal LS174T cells. | 2010 Oct 9 |
1 |
| 74 |
19183931 | [Drug-drug interactions in urology]. | 2009 Mar |
1 |
| 75 |
19343062 | Effect of bifendate on the pharmacokinetics of cyclosporine in relation to the CYP3A4*18B genotype in healthy subjects. | 2009 Apr |
6 |
| 76 |
19667964 | Pharmacogenetics of calcineurin inhibitors in renal transplantation. | 2009 Aug 15 |
1 |
| 77 |
19728747 | Immunotherapy in elderly transplant recipients: a guide to clinically significant drug interactions. | 2009 |
1 |
| 78 |
19729463 | Incidence, predictors and associated outcomes of rhabdomyolysis after kidney transplantation. | 2009 Dec |
1 |
| 79 |
20038391 | [Pharmacogenetic analysis of the absorption kinetics of cyclosporine in a population of Spanish cardiac transplant patients]. | 2009 Nov-Dec |
1 |
| 80 |
18076219 | Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects. | 2008 |
1 |
| 81 |
18192894 | Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms. | 2008 Feb |
1 |
| 82 |
18223473 | Everolimus exposure in cardiac transplant recipients is influenced by concomitant calcineurin inhibitor. | 2008 Feb |
1 |
| 83 |
18518855 | A drug transporter for all ages? ABCB1 and the developmental pharmacogenetics of cyclosporine. | 2008 Jun |
1 |
| 84 |
18608282 | Colchicine-induced toxicity in a heart transplant patient with chronic renal failure. | 2008 Nov |
2 |
| 85 |
18636247 | Association of MDR1, CYP3A4*18B, and CYP3A5*3 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients. | 2008 Nov |
2 |
| 86 |
18665658 | Secondary prevention of coronary heart disease in elderly patients following myocardial infarction: are all HMG-CoA reductase inhibitors alike? | 2008 |
1 |
| 87 |
18721002 | Cinacalcet does not affect the activity of cytochrome P450 3A enzymes, a metabolic pathway for common immunosuppressive agents : a randomized, open-label, crossover, single-centre study in healthy volunteers. | 2008 |
1 |
| 88 |
18978522 | CYP3A7, CYP3A5, CYP3A4, and ABCB1 genetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipients. | 2008 Dec |
6 |
| 89 |
19005401 | Haplotypic structure of ABCB1/MDR1 gene modifies the risk of the acute allograft rejection in renal transplant recipients. | 2008 Nov 15 |
1 |
| 90 |
17151193 | Metabolism of sirolimus in the presence or absence of cyclosporine by genotyped human liver microsomes and recombinant cytochromes P450 3A4 and 3A5. | 2007 Mar |
1 |
| 91 |
17202802 | Effect of cyclosporine and tacrolimus on cytochrome p450 activities in human liver microsomes. | 2007 Jan |
1 |
| 92 |
17244767 | Effect of a single cyclosporine dose on the single-dose pharmacokinetics of sitagliptin (MK-0431), a dipeptidyl peptidase-4 inhibitor, in healthy male subjects. | 2007 Feb |
1 |
| 93 |
17374625 | Does metronidazole interact with CYP3A substrates by inhibiting their metabolism through this metabolic pathway? Or should other mechanisms be considered? | 2007 Apr |
1 |
| 94 |
17425754 | Multi-drug resistance gene-1 (MDR-1) haplotypes and the CYP3A5*1 genotype have no influence on ciclosporin dose requirements as assessed by C0 or C2 measurements. | 2007 Mar-Apr |
1 |
| 95 |
17545536 | A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871. | 2007 Jun 1 |
1 |
| 96 |
17624028 | Association of CYP3A4*18B polymorphisms with the pharmacokinetics of cyclosporine in healthy subjects. | 2007 Mar |
3 |
| 97 |
18240909 | Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update. | 2007 Jul |
1 |
| 98 |
16611021 | Evaluation of microsomal incubation conditions on CYP3A4-mediated metabolism of cyclosporine A by a statistical experimental design. | 2006 Apr |
2 |
| 99 |
16612333 | The influence of CYP3A gene polymorphisms on cyclosporine dose requirement in renal allograft recipients. | 2006 May |
3 |
| 100 |
16634729 | Withdrawal symptoms from transdermal fentanyl (TDF) after an allogeneic peripheral blood stem cell transplant (PBSCT). | 2006 Mar-Apr |
1 |